G-BA: Orphan Signifor has 'marginal' additional benefit

Germany's Federal Joint Committee (G-BA) issued a final assessment that said Signifor pasireotide from Novartis AG (NYSE:NVS; SIX:NOVN) provides a "marginal" degree of additional benefit for patients with Cushing's disease for whom surgery is not an option or has failed -- its approved indication. Novartis will now negotiate a price for the Orphan drug, a somatostatin analog, with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband). ...